HomeAI · summaries
Storia in 3 fonti
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
- ·
morningstar.com
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis…
- ·
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic…
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
- ·
endpoints.news
IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport
Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.